These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31174994)

  • 1. Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China.
    Zhang H; Tan J; Kontoyiannis DP; Zhou Y; Liu W; Zhu P; Shi X; Wan Z; Li R; Liu W
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):166-170. PubMed ID: 31174994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
    J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal susceptibility of clinical isolates of 25 genetically confirmed Aspergillus species collected from Taiwan and Mainland China.
    Li Y; Wang H; Zhao YP; Xu YC; Hsueh PR
    J Microbiol Immunol Infect; 2020 Feb; 53(1):125-132. PubMed ID: 29844003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of Azole Resistance Involving
    Ghorbel D; Amouri I; Khemekhem N; Neji S; Trabelsi H; Elloumi M; Sellami H; Makni F; Ayadi A; Hadrich I
    Pol J Microbiol; 2024 Jun; 73(2):131-142. PubMed ID: 38700908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.
    Howard SJ; Lass-Flörl C; Cuenca-Estrella M; Gomez-Lopez A; Arendrup MC
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5426-31. PubMed ID: 23959309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey.
    Rambach G; Oberhauser H; Speth C; Lass-Flörl C
    Med Mycol; 2011 Nov; 49(8):856-63. PubMed ID: 21619497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of the polymorphism of cyp51A sequence and the susceptibility of Aspergillus fumigatus isolates to triazoles determined by commercial gradient test (Etest) and by reference methods.
    Nawrot U; Sulik-Tyszka B; Kurzyk E; Mroczyńska M; Włodarczyk K; Wróblewska M; Basak GW; Brillowska-Dąbrowska A
    Acta Biochim Pol; 2017; 64(4):631-634. PubMed ID: 29202140
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Gao L; Xia X; Gong X; Zhang H; Sun Y
    Front Cell Infect Microbiol; 2024; 14():1296151. PubMed ID: 38304196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates.
    Carrillo-Muñoz AJ; Tur-Tur C; Hernández-Molina JM; Quindós G; Marcos-Arias C; Eraso E; Cárdenes D; Ortiz-Maestro O; Santos P; Estivill D; Guardia C; Giusiano G
    Rev Esp Quimioter; 2010 Sep; 23(3):122-5. PubMed ID: 20844842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
    Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
    Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration.
    Arendrup MC; Jensen RH; Grif K; Skov M; Pressler T; Johansen HK; Lass-Flörl C
    J Infect Dis; 2012 Sep; 206(6):981-5. PubMed ID: 22782947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
    Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
    Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait.
    Ahmad S; Khan Z; Hagen F; Meis JF
    Environ Res; 2014 Aug; 133():20-6. PubMed ID: 24906064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Point Mutations in
    Abastabar M; Hosseini T; Valadan R; Lagzian M; Haghani I; Aslani N; Badali H; Nouripour-Sisakht S; Nazeri M; Gholami S; Vakili M; Bowyer P; Shokohi T; Hedayati MT
    Microb Drug Resist; 2019 Jun; 25(5):652-662. PubMed ID: 30657433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.